Loren Pickart's foundational 1973 characterization of GHK as a plasma growth-promoting peptide opened a research line that now extends across wound healing, skin remodeling, antioxidant gene expression, and anti-inflammatory regulation [9,10]
La forma "GRF modificado 1-29" del CJC-1295 (sin DAC, como en esta mezcla) tiene una vida media plasmtica (half-life) de aproximadamente 30 minutos
Other mechanisms include increased insulin resistance induced by high-dose glucocorticoids that increases intra-portal insulin, decreases IGFBP-1 that increases free IGF-I, and direct glucocorticoid effects in increasing hepatic IGF-I synthesis and decreasing hepatic insulin clearance (105)
Rather than targeting growth hormone pathways directly, this combination is typically examined in models related to tissue repair and structural support
Grossini E, De Marchi F, Venkatesan S, et al